Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1377-1385

  Brunner, Hermine I ^a   Silva, Clovis A ^b   Reiff, Andreas ^c   Higgins, Gloria C ^d   Imundo, Lisa ^e   Williams, Calvin B ^f   Wallace, Carol A ^g   Aikawa, Nadia E ^b   Nelson, Shannen ^a   Klein Gitelman, Marisa S ^h   Rose, Susan R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Department of Medicine   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; INHIBIN B; LUTEINIZING HORMONE; PLACEBO; TRIPTORELIN; ANTIRHEUMATIC AGENT; LUTEOLYTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CELLULITIS; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERTENSION; INFECTION COMPLICATION; INJECTION SITE REACTION; LEG EDEMA; LYMPHATIC SYSTEM DISEASE; MAINTENANCE THERAPY; MEDIASTINUM DISEASE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; ORGANIC BRAIN SYNDROME; OUTCOME ASSESSMENT; OVARIAN PRESERVATION; OVARIAN RESERVE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX DISEASE; THORAX PAIN; TIME TO TREATMENT; VASCULAR DISEASE; VASCULITIS; YOUNG ADULT; CHEMICALLY INDUCED; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; OVULATION INHIBITION; PRIMARY OVARIAN INSUFFICIENCY; TIME;

ADOLESCENT; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUTEINIZING HORMONE; LUTEOLYTIC AGENTS; OVULATION INHIBITION; PRIMARY OVARIAN INSUFFICIENCY; TIME FACTORS; TRIPTORELIN PAMOATE; YOUNG ADULT;

EID: 84928637462     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39024     Document Type: Article

References (30)

1. Fernandes Moca Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah AN,. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Sys Rev 2013; 2: CD002265.
2. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 375-83.
3. Koo HS, Kim YC, Lee SW, Kim DK, Oh KH, Joo KW, et al. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus 2011; 20: 1442-9.
4. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM., Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002; 29: 2129-35.
5. Manger K, Wildt L, Kalden JR, Manger B., Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2006; 5: 269-72.
6. Silva CA, Brunner HI., Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus. Lupus 2007; 16: 593-9.
7. Isgro J, Nurudeen SK, Imundo LF, Sauer MV, Douglas NC., Cyclophosphamide exposure in pediatric systemic lupus erythematosus is associated with reduced serum anti-mullerian hormone levels. J Rheumatol 2013; 40: 1029-31.
8. Blumenfeld Z, Mischari O, Schultz N, Boulman N, Balbir-Gurman A., Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Sem Arthritis Rheum 2011; 41: 346-52.
9. Van Gool SA, Kamp GA, Visser-van Balen H, Mul D, Waelkens JJ, Jansen M, et al. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab 2007; 92: 1402-8.
10. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M., Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401-5.
11. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ., Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005; 52: 2761-7.
12. Sinha R, Dionne JM., Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy? Arch Disease Child 2008; 93: 444-5.
13. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
14. Silva CA, Bonfa E, Ostensen M. Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs. Arthritis Care Res (Hoboken) 2010; 62: 1682-90.
15. Lahlou N., [Pharmacokinetics and pharmacodynamics of triptorelin]. Ann Urol (Paris) 2005; 39Suppl3: S78-84.
16. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010; 95: 109-17.
17. Blumenfeld Z, Dann E., GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma. J Clin Oncol 2013; 31: 3721.
18. Sathasivam A, Garibaldi L, Shapiro S, Godbold J, Rapaport R., Leuprolide stimulation testing for the evaluation of early female sexual maturation. Clin Endocrinol (Oxf) 2010; 73: 375-81.
19. Rosenfield RL, Bordini B, Yu C., Comparison of detection of normal puberty in girls by a hormonal sleep test and a gonadotropin-releasing hormone agonist test. J Clin Endocrinol Metab 2013; 98: 1591-601.
20. Randolph JF Jr, Harlow SD, Helmuth ME, Zheng H, McConnell DS., Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle. Hum Reprod 2014; 29: 592-600.
21. ACM Medical Laboratory Reference Manual. URL: http://referencemanual.acmlab.com/.
22. Brunner H, Silverman E, To T, Bombardier C, Feldman BM., Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-44.
23. Kovacs M., The Children's Depression Inventory (CDI). Psychopharmacol Bull 1985; 21: 995-8.
24. Beck AT, Steer RA, Ball R, Ranieri W., Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67: 588-97.
25. Van Leudsen H., Dose response of decapeptyl depot using three dosage regimens in gynecological patients (Study 45 CO2/PR/15). Ferring Internat Report 1993.
26. Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME., The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 2013; 22: 81-6.
27. Partsch CJ, Sippell WG., Treatment of central precoccious puberty. Best Pract Res Endocrinol 2002; 16: 165-89.
28. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R., Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008; 93: 190-5.
29. Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013; 31: 903-9.
30. Mok CC, Wong RW, Lau CS., Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1274-80.